AR125264A1 - Agentes aglutnantes dirigidos a tumores y/o células inmunitarias - Google Patents
Agentes aglutnantes dirigidos a tumores y/o células inmunitariasInfo
- Publication number
- AR125264A1 AR125264A1 ARP220100796A ARP220100796A AR125264A1 AR 125264 A1 AR125264 A1 AR 125264A1 AR P220100796 A ARP220100796 A AR P220100796A AR P220100796 A ARP220100796 A AR P220100796A AR 125264 A1 AR125264 A1 AR 125264A1
- Authority
- AR
- Argentina
- Prior art keywords
- binding agents
- immune cells
- tumors
- present disclosure
- agents targeted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163168606P | 2021-03-31 | 2021-03-31 | |
| US202163249784P | 2021-09-29 | 2021-09-29 | |
| US202263301305P | 2022-01-20 | 2022-01-20 | |
| PCT/CA2022/050442 WO2022204793A1 (en) | 2021-03-31 | 2022-03-25 | Binding agents targeting tumors and/or immune cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125264A1 true AR125264A1 (es) | 2023-06-28 |
Family
ID=83455216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100796A AR125264A1 (es) | 2021-03-31 | 2022-03-31 | Agentes aglutnantes dirigidos a tumores y/o células inmunitarias |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240166739A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4314076A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024512741A (cg-RX-API-DMAC7.html) |
| AR (1) | AR125264A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3174330A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202304993A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022204793A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4599066A1 (en) * | 2022-10-03 | 2025-08-13 | Kisoji Biotechnology Inc. | Multispecific binding agents targeting dopamine receptor d2 and methods of use thereof |
| CN120265659A (zh) * | 2022-10-25 | 2025-07-04 | 加拿大商木曾路生物科技公司 | 靶向表达cd36的肿瘤细胞的结合剂 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009508521A (ja) * | 2005-09-23 | 2009-03-05 | アカデミッシュ ジーケンハイス レイデン | タンパク凝集に関連する疾患の診断予防及び治療のためのvhh |
| CA2747644C (en) * | 2008-12-19 | 2023-01-24 | Ablynx N.V. | Method for generation of immunoglobulin sequences |
| WO2011051327A2 (en) * | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
| US20180222966A1 (en) * | 2013-04-29 | 2018-08-09 | Agrosavfe N.V. | Transgenic plant comprising a polynucleotide encoding a variable domain of heavy-chain antibody |
| US10874685B2 (en) * | 2014-04-17 | 2020-12-29 | The Royal Institution For The Advancement Of Learning/Mcgill University | Pancreatic cancer therapy and diagnosis |
| CA2975655C (en) * | 2015-02-05 | 2023-09-19 | Janssen Vaccines & Prevention B.V. | Binding molecules directed against influenza hemagglutinin and uses thereof |
| CA3065999A1 (en) * | 2017-05-24 | 2018-11-29 | Nanosomix, Inc. | Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders |
| WO2019179434A1 (en) * | 2018-03-20 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific pd-1/cd47 antibody molecules |
| CN114072426B (zh) * | 2019-07-08 | 2024-01-26 | 南京金斯瑞生物科技有限公司 | 抗cd47/抗pd-1双特异抗体及其制备方法和应用 |
-
2022
- 2022-03-25 EP EP22778240.6A patent/EP4314076A4/en active Pending
- 2022-03-25 WO PCT/CA2022/050442 patent/WO2022204793A1/en not_active Ceased
- 2022-03-25 US US18/283,579 patent/US20240166739A1/en active Pending
- 2022-03-25 JP JP2023560694A patent/JP2024512741A/ja active Pending
- 2022-03-25 CA CA3174330A patent/CA3174330A1/en active Pending
- 2022-03-31 AR ARP220100796A patent/AR125264A1/es unknown
- 2022-03-31 TW TW111112543A patent/TW202304993A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240166739A1 (en) | 2024-05-23 |
| CA3174330A1 (en) | 2022-09-30 |
| EP4314076A1 (en) | 2024-02-07 |
| JP2024512741A (ja) | 2024-03-19 |
| WO2022204793A1 (en) | 2022-10-06 |
| TW202304993A (zh) | 2023-02-01 |
| EP4314076A4 (en) | 2025-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124437T1 (el) | Ανθρωπινα αντισωματα κατα toy pd-l1 | |
| PE20241170A1 (es) | Anticuerpo triespecifico dirigido a bcma, gprc5d, y cd3 | |
| EA202091888A1 (ru) | Вариабельные домены антител, нацеленные на рецептор nkg2d | |
| DOP2020000128A (es) | Anticuerpos anti-trem2 y métodos relacionados | |
| WO2018023025A8 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| MX2019012461A (es) | Anticuerpo anti-pd-l1 y uso del mismo. | |
| PE20241349A1 (es) | Anticuerpos de union a cd3 | |
| MX2020013606A (es) | Constructos de anticuerpos multiespecificos. | |
| CY1122210T1 (el) | Ανθρωπινα αντισωματα anti-sod1 | |
| BR112022009723A2 (pt) | Anticorpos específicos para cd47, pd-l1, e usos dos mesmos | |
| MX2020008336A (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. | |
| EA202092044A1 (ru) | Химерные рецепторы антигена против cd33 и их применения | |
| CY1119994T1 (el) | Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α | |
| CO2017011486A2 (es) | Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales | |
| MX2022008925A (es) | Anticuerpos anti-pd-l1. | |
| CY1113037T1 (el) | Ανθρωπινο αντισωμα αντι-υποδοχεα επιδερμικου αυξητικου παραγοντα | |
| CO2023013511A2 (es) | Anticuerpo triespecífico dirigido a cd79b, cd20, y cd3 | |
| MX378944B (es) | Anticuerpos de antígeno anti-tf humanizado. | |
| MX2020010913A (es) | Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos. | |
| MX2021009138A (es) | Anticuerpos anti-cd228 y conjugados de anticuerpo-farmaco. | |
| AR118720A1 (es) | Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3 | |
| AR103428A1 (es) | Anticuerpos de penetración celular | |
| MY204733A (en) | Anti-pd-l1 antibodies and use thereof | |
| EA202190573A1 (ru) | Композиции и способы перепрограммирования tcr с применением гибридных белков | |
| EP4335872A4 (en) | BI-SPECIFIC ANTIBODY BINDING SPECIFICALLY TO CD47 AND PD-L1 |